دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Immune Checkpoint Inhibitors in Ovarian Cancer: Can We Bridge the Gap Between IMagynation and Reality?
Panagiotis A. Konstantinopoulos , MD, PhDand Stephen A. Cannistra, MD
doi : 10.1200/JCO.21.00571
Journal of Clinical Oncology 39, no. 17 (June 10, 2021) 1833-1838.
Is This the Dawn of Precision Oncology in Head and Neck Cancer?
Alexander T. Pearson , MD, PhD and Everett E. Vokes , MD
doi : 10.1200/JCO.21.00569
Journal of Clinical Oncology 39, no. 17 (June 10, 2021) 1839-1841.
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)
Kathleen N. Moore , MD1,2; Michael Bookman , MD3; Jalid Sehouli, MD4; Austin Miller, PhD5; Charles Anderson, MD6; Giovanni Scambia , MD7; Tashanna Myers , MD8; Cagatay Taskiran, MD9,10; Katina Robison, MD11; Johanna M?enp?? , MD12; Lyndsay Willmott, MD13; Nicoletta Colombo , MD14; Jessica Thomes-Pepin, MD15; Michalis Liontos , MD16; Michael A. Gold, MD17; Yolanda Garcia, MD18; Sudarshan K. Sharma, MD19; Christopher J. Darus, MD20; Carol Aghajanian, MD21; Aikou Okamoto, MD22; Xiaohua Wu , MD23; Rustem Safin, MD24; Fan Wu, MS25; Luciana Molinero , MD26; Vidya Maiya, MD26; Victor K. Khor, PhD26; Yvonne G. Lin, MD26; and Sandro Pignata , MD27
doi : 10.1200/JCO.21.00306
Journal of Clinical Oncology 39, no. 17 (June 10, 2021) 1842-1855.
To evaluate the addition of the humanized monoclonal antiprogrammed death ligand-1 (PD-L1) antibody, atezolizumab, to platinum-based chemotherapy and bevacizumab in newly diagnosed stage III or IV ovarian cancer (OC).
Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations
Alan L. Ho , MD, PhD1,2; Irene Brana , MD3; Robert Haddad , MD4; Jessica Bauman, MD5; Keith Bible , MD6; Sjoukje Oosting, MD7; Deborah J. Wong, MD, PhD8; Myung-Ju Ahn, MD, PhD9; Valentina Boni , MD, PhD10; Caroline Even, MD11; Jerome Fayette, MD12; Maria José Flor, MD13; Kevin Harrington , PhD14; Sung-Bae Kim , MD, PhD15; Lisa Licitra , MD16; Ioanna Nixon, MD, PhD, MPH17; Nabil F. Saba , MD18; Stephan Hackenberg, MD19; Pol Specenier, MD, PhD20; Francis Worden, MD21; Binaifer Balsara, PhD22; Mollie Leoni, MD22; Bridget Martell, MA, MD22; Catherine Scholz, PharmD22; and Antonio Gualberto , MD, PhD22
doi : 10.1200/JCO.20.02903
Journal of Clinical Oncology 39, no. 17 (June 10, 2021) 1856-1864.
Mutations in the HRAS (mHRAS) proto-oncogene occur in 4%-8% of patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Tipifarnib is a farnesyltransferase inhibitor that disrupts HRAS function. We evaluated the efficacy of tipifarnib in patients with R/M mHRAS HNSCC.
Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD
Benjamin Watkins, MD1; Muna Qayed, MD1; Courtney McCracken, PhD2; Brandi Bratrude, BA3; Kayla Betz, BS3; Yvonne Suessmuth, PhD1; Alison Yu, PhD3; Shauna Sinclair4; Scott Furlan, MD5; Steven Bosinger, PhD6; Victor Tkachev, PhD3; James Rhodes, PharmD7; Audrey Grizzle Tumlin, BS7; Alexandria Narayan, BA5; Kayla Cribbin, BS4; Scott Gillespie, MS2; Ted A. Gooley, PhD5; Marcelo C. Pasquini, MD8; Kyle Hebert, MS8; Urvi Kapoor, MD9; Andre Rogatko, PhD10; Mourad Tighiouart, PhD10; Sungjin Kim, MS10; Catherine Bresee, MS10; Sung W. Choi, MD11; Jeffrey Davis, MD12; Christine Duncan, MD3; Roger Giller, MD13; Michael Grimley, MD14; Andrew C. Harris, MD15; David Jacobsohn, MD16; Nahal Lalefar, MD17; Maxim Norkin, MD18; Nosha Farhadfar, MD19; Michael A. Pulsipher, MD20; Shalini Shenoy, MD21; Aleksandra Petrovic, MD4; Kirk R. Schultz, MD12; Gregory A. Yanik, MD11; Edmund K. Waller, MD22; John E. Levine, MD9; James L. Ferrara, MD9; Bruce R. Blazar, MD23; Amelia Langston, MD22; John T. Horan, MD3; and Leslie S. Kean, MD, PhD3 Benjamin Watkins, MD1; Muna Qayed, MD1; Courtney McCracken, PhD2; Brandi Bratrude, BA3; Kayla Betz, BS3; Yvonne Suessmuth, PhD1; Alison Yu, PhD3; Shauna Sinclair4; Scott Furlan, MD5; Steven Bosinger, PhD6; Victor Tkachev, PhD3; James Rhodes, PharmD7; Audrey Grizzle Tumlin, BS7; Alexandria Narayan, BA5; Kayla Cribbin, BS4; Scott Gillespie, MS2; Ted A. Gooley, PhD5; Marcelo C. Pasquini, MD8; Kyle Hebert, MS8; Urvi Kapoor, MD9; Andre Rogatko, PhD10; Mourad Tighiouart, PhD10; Sungjin Kim, MS10; Catherine Bresee, MS10; Sung W. Choi, MD11; Jeffrey Davis, MD12; Christine Duncan, MD3; Roger Giller, MD13; Michael Grimley, MD14; Andrew C. Harris, MD15; David Jacobsohn, MD16; Nahal Lalefar, MD17; Maxim Norkin, MD18; Nosha Farhadfar, MD19; Michael A. Pulsipher, MD20; Shalini Shenoy, MD21; Aleksandra Petrovic, MD4; Kirk R. Schultz, MD12; Gregory A. Yanik, MD11; Edmund K. Waller, MD22; John E. Levine, MD9; James L. Ferrara, MD9; Bruce R. Blazar, MD23; Amelia Langston, MD22; John T. Horan, MD3; and Leslie S. Kean, MD, PhD3
doi : 10.1200/JCO.20.01086
Journal of Clinical Oncology 39, no. 17 (June 10, 2021) 1865-1877.
Severe (grade 3-4) acute graft-versus-host disease (AGVHD) is a major cause of death after unrelated-donor (URD) hematopoietic cell transplant (HCT), resulting in particularly high mortality after HLA-mismatched transplantation. There are no approved agents for AGVHD prevention, underscoring the critical unmet need for novel therapeutics. ABA2 was a phase II trial to rigorously assess safety, efficacy, and immunologic effects of adding T-cell costimulation blockade with abatacept to calcineurin inhibitor (CNI)/methotrexate (MTX)-based GVHD prophylaxis, to test whether abatacept could decrease AGVHD.
Acute GVHD Diagnosis and Adjudication in a Multicenter Trial: A Report From the BMT CTN 1202 Biorepository Study
Ran Reshef, MD, MSc1; Wael Saber, MD, MS2; Javier Bola?os-Meade, MD3; George Chen, MD4; Yi-Bin Chen, MD5; Vincent T. Ho, MD6; Doris M. Ponce, MD7; Ryotaro Nakamura, MD8; Michael J. Martens, PhD9; John A. Hansen, MD10,11 †; and John E. Levine, MD12 Ran Reshef, MD, MSc1; Wael Saber, MD, MS2; Javier Bola?os-Meade, MD3; George Chen, MD4; Yi-Bin Chen, MD5; Vincent T. Ho, MD6; Doris M. Ponce, MD7; Ryotaro Nakamura, MD8; Michael J. Martens, PhD9; John A. Hansen, MD10,11 †; and John E. Levine, MD12
doi : 10.1200/JCO.20.00619
Journal of Clinical Oncology 39, no. 17 (June 10, 2021) 1878-1887.
Accurate and reproducible methods to diagnose, grade, and report acute graft-versus-host disease (GVHD) are critical for the evaluation of therapies and biomarkers.
ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease
Madan Jagasia , MD, MS1; Aleksandr Lazaryan , MD, MPH, PhD2; Carlos R. Bachier, MD3; Amandeep Salhotra, MD4; Daniel J. Weisdorf , MD5; Behyar Zoghi, MD, PhD6; James Essell, MD7; Laurie Green, MEd8; Olivier Schueller, PhD8; Jeegar Patel, PhD8; Alexandra Zanin-Zhorov, PhD8; Jonathan M. Weiss, PhD8; Zhongming Yang, PhD8; David Eiznhamer, PhD8; Sanjay K. Aggarwal, MD8; Bruce R. Blazar , MD9; and Stephanie J. Lee , MD, MPH10
doi : 10.1200/JCO.20.02754
Journal of Clinical Oncology 39, no. 17 (June 10, 2021) 1888-1898.
The rho-associated coiled-coil–containing protein kinase-2 (ROCK2) signaling pathway regulates the Th17/regulatory T cells balance and controls profibrotic pathways. Selective ROCK2 inhibition with belumosudil (KD025) may offer a novel approach to the management of chronic graft-versus-host disease (cGVHD).
Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial
Mikael Eriksson , PhD1; Martin Eklund, PhD1; Signe Borgquist , MD, PhD2,3; Roxanna Hellgren , MD4; Sara Margolin, MD, PhD5,6; Linda Thoren, MD5,6; Ann Rosendahl , PhD3; Kristina L?ng , MD, PhD7,8; José Tapia , MS1; Magnus B?cklund, MD, PhD1; Andrea Discacciati, PhD1; Alessio Crippa , PhD1; Marike Gabrielson , PhD1; Mattias Hammarstr?m, BSc1; Yvonne Wengstr?m, PhD9; Kamila Czene, PhD1; and Per Hall , MD, PhD1,5
doi : 10.1200/JCO.20.02598
Journal of Clinical Oncology 39, no. 17 (June 10, 2021) 1899-1908.
Tamoxifen prevents breast cancer in high-risk women and reduces mortality in the adjuvant setting. Mammographic density change is a proxy for tamoxifen therapy response. We tested whether lower doses of tamoxifen were noninferior to reduce mammographic density and associated with fewer symptoms.
Management of Salivary Gland Malignancy: ASCO Guideline
Jessica L. Geiger, MD1; Nofisat Ismaila , MD2; Beth Beadle , MD, PhD3; Jimmy J. Caudell, MD, PhD4; Nicole Chau, MD5; Daniel Deschler, MD6; Christine Glastonbury, MBBS7; Marnie Kaufman 8; Eric Lamarre, MD1; Harold Y. Lau , MD9; Lisa Licitra , MD10,11; Michael G. Moore, MD12; Cristina Rodriguez, MD13; Anna Roshal, MD14; Raja Seethala, MD15; Paul Swiecicki , MD16; and Patrick Ha , MD7
doi : 10.1200/JCO.21.00449
Journal of Clinical Oncology 39, no. 17 (June 10, 2021) 1909-1941.
To provide evidence-based recommendations for practicing physicians and other healthcare providers on the management of salivary gland malignancy.
Treating Inflammation and Fibrosis in Chronic GVHD: Two Birds, One ROCK
Corey Cutler, MD, MPH1
doi : 10.1200/JCO.21.00214
Journal of Clinical Oncology 39, no. 17 (June 10, 2021) 1942-1945.
What Is the Optimal Model to Estimate the Benefits of Chemotherapy in Patients With Hormone Receptor–Positive, HER2-Negative, Node-Negative Breast Cancer?
Kenju Ando, MD, Akihiko Shimomura , MD, PhD, Kenichi Yoshimura, PhD, Yukino Kawamura , MD, and Chikako Shimizu, MD, PhD
doi : 10.1200/JCO.21.00178
Journal of Clinical Oncology 39, no. 17 (June 10, 2021) 1946-1947.
Reply to K. Ando et al
Joseph A. Sparano , MD, Michael R. Crager , PhD, Gong Tang , PhD, Robert J. Gray , PhD, Salomon M. Stemmer, MD, and Steven Shak, MD
doi : 10.1200/JCO.21.00424
Journal of Clinical Oncology 39, no. 17 (June 10, 2021) 1947-1948.
Erratum
empty
doi : 10.1200/JCO.21.01150
Journal of Clinical Oncology 39, no. 17 (June 10, 2021) 1949-1949.
